

IN THE SPECIFICATION

Amend the specification as follows:

Page 1, line 1, insert the following new paragraph:

This application is a divisional of Application Serial No. 10/044,995, filed January 15, 2002 (pending), which is divisional of Application No. 09/941,611, filed August 30, 2001 (now U.S. Patent No. 6,576,417), which in turn is a divisional of Application No. 09/275,265, filed March 23, 1999 (now U.S. Patent No. 6,287,761), which in turn is a continuation of Application No. 08/391,671 filed February 21, 1995 (now U.S. Patent 5,922,532), which is a continuation of Application No. 07/920,286, filed October 14, 1992, abandoned, which is a 371 of PCT/EP91/02409, filed December 31, 1991, which claims benefit of EP 90124241, filed December 14, 1990. Issued U.S. Patent Nos. 5910404 and 6007982 are similarly continuation applications of Application No. 08/391,671 filed February 21, 1995 (now U.S. Patent 5,922,532), which is a continuation of Application No. 07/920,286, filed October 14, 1992, abandoned, which is a 371 of PCT/EP91/02409, filed December 13, 1991, which claims benefit of EP 90124241, filed December 14, 1990. The entirety of each of the above-identified applications and patents are hereby incorporated by reference herein.

Delete the second and third full paragraphs (lines 6-11) on page 3 and insert the following in its place:

Figures 1A - 1D ~~shows~~ show the amino acid sequences of the composite HCV_{HC-J1/CDC/CH1} (SEQ ID NO:23)

Figures 2A-2L ~~shows~~ show the antibody binding to individual peptides and various mixtures in an ELISA assay. Coating combinations used for Figures 2A - 2L are as follows:

1 : IX, 2 : XVIII, 3 : I, 4 : III, 5 : V, 6 : IX + XVIII, 7 : I + XVIII, 8 : I + III + IX, 9 : I + III + V + XVIII, 10 : I + III + V + IX, 11 : I + III + IX + XVIII, 12 : I + III + V + IX + XVIII.

Page 5, delete the paragraphs spanning lines 19-26 and insert the following therefor:

Peptide I, shown in SEQ ID NO:1, corresponds to amino acids 1 to 20 and has the following amino acid ~~sequences~~ sequence:

(I)

Y-Met-Ser-Thr-Ile-Pro-Lys-Pro-Gln-Arg-Lys-Thr-Lys-Arg-Asn-Thr-Asn-Arg-Arg-Pro-Gln-Z-X.

Peptide I, shown in SEQ ID NO:1, corresponds to amino acids 7 to 26 and has the amino acid sequence:

Page 6, delete the paragraph at line 1 and insert the following therefor:

DeLeys et al
Divisional of Serial No. 10/044,995
April 13, 2004

Of particular interest is the oligopeptide IIA, shown in SEQ ID NO:3, which has the sequence

Page 6, delete the paragraph at line 6 and insert the following therefor:

Peptide III, shown in SEQ ID NO:4, corresponds to amino acids 13 to 32 and has the sequence:

Page 6, delete the paragraph at line 11 and insert the following therefor:

Peptide IV, shown in SEQ ID NO:5, corresponds to amino acid 37 to 56 and has the sequence sequence:

Page 6, delete the paragraph at line 16, and insert the following:

Peptide V, shown in SEQ ID NO:6, corresponds to amino acids 49 to 68 and has the sequence:

Page 6, delete the paragraph spanning lines 21 and 22 and insert the following therefor:

Peptide VI, shown in SEQ ID NO:7, corresponds to amino acid 61 to 80 and has the following sequence:

Page 6, delete the paragraph at line 27 and insert the following therefor:

Peptide VII, shown in SEQ ID NO:8, corresponds to amino acids 73 to 92 and has the sequence:

Page 7, delete the paragraph spanning lines 1 and 2 and insert the following therefore:

Peptide VIII, shown in SEQ ID NO:9, corresponds to amino acids 1688 to 1707 and has the sequence:

Page 7, delete the paragraph spanning lines 7 and 8 and insert the following therefor:

Peptide IX, shown in SEQ ID NO:10, corresponds to amino acids 1694 to 1713 and has the sequence:

Page 7, delete the paragraph spanning lines 13 and 14 and insert the following therefor:

Peptide X, shown in SEQ ID NO:11, corresponds to amino acids 1706 to 1725 and has the sequence:

Page 7, delete the paragraph spanning lines 19 and 20 and insert the following therefor:

Peptide XI, shown in SEQ ID NO:12, corresponds to amino acids 1712 to 1731 and has the sequence:

Page 7, delete the paragraph spanning lines 25 and 26 and insert the following therefor:

Peptide XII, shown in SEQ ID NO:13, corresponds to amino acids 1718 to 1737 and has the sequence:

Page 8, delete the paragraph spanning lines 1 and 2 and insert the following therefor:

Peptide XIII, shown in SEQ ID NO:14, corresponds to amino acids 1724 to 1743 and has the sequence:

Page 8, delete the paragraph spanning lines 7 and 8 and insert the following therefor:

Peptide XIV, shown in SEQ ID NO:15, corresponds to amino acids 1730 to 1749 and has the sequence:

Page 8, delete the paragraph spanning lines 13 and 14 and insert the following therefor:

Peptide XV, shown in SEQ ID NO:16, corresponds to amino acids 2263 to 2282 and has the sequence:

Page 8, delete the paragraph spanning lines 19 and 20 and insert the following therefor:

Peptide XVI, shown in SEQ ID NO:17, corresponds to amino acids 2275 to 2284 and has the sequence:

Page 8, delete the paragraph spanning lines 26 and 27 and insert the following therefor:

Peptide XVII, shown in SEQ ID NO:18, corresponds to amino acids 2287 to 2306 and has the sequence:

Page 9, delete the paragraph spanning lines 1 and 2 and insert the following therefor:

Peptide XVIII, shown in SEQ ID NO:19, corresponds to amino acids 2299 to 2318 and has the sequence:

Page 9, delete the paragraph spanning lines 7 and 8 and insert the following therefor:

Peptide XIX, shown in SEQ ID NO:20, corresponds to amino acids 2311 to 2330 and has the sequence:

Insert the attached Sequence Listing after the claims pages.